Calidi Biotherapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Calidi Biotherapeutics, Inc. (CLDI) reported Marketable Securities, Unrealized Gain (Loss) of $40.83 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-08-21
- Calidi Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-06-30 was $12.85K.
- Calidi Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $27.99K, a 1135.04% increase year-over-year.
- Calidi Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was $134.54K, a 4897.77% increase year-over-year.
- Calidi Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was -$2.27K, a 635.70% decline year-over-year.
- Calidi Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was $134.54K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | $12.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $40.83K 10-Q · filed 2023-08-21 | $175.37K derived: sum of 3 quarters · filed 2023-08-21 | $173.11K derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | $27.99K 10-Q · filed 2023-05-15 | $162.53K derived: sum of 2 quarters · filed 2023-05-15 | $160.26K derived: sum of 3 quarters · filed 2023-05-15 | $160.26K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-12-31 | $134.54K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $132.27K derived: sum of 2 quarters · filed 2023-03-31 | $132.27K derived: sum of 3 quarters · filed 2023-08-21 | $134.54K 10-K · filed 2023-03-31 |
| 2022-09-30 | -$2.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.27K derived: sum of 2 quarters · filed 2023-08-21 | $0.00 10-Q · filed 2022-11-14 | $2.69K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $2.27K 10-Q · filed 2023-08-21 | $4.96K derived: sum of 3 quarters · filed 2023-08-21 | $5.38K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $2.27K 10-Q · filed 2023-05-15 | $4.96K derived: sum of 2 quarters · filed 2023-05-15 | $5.38K derived: sum of 3 quarters · filed 2023-05-15 | $5.38K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.69K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $3.12K derived: sum of 2 quarters · filed 2023-03-31 | $3.12K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $423.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $423.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |